Barclays lowered the firm’s price target on AstraZeneca to 125 GBp from 135 GBp and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca (AZN) Announces Q1 Dividend: Read On for Important Dates
- Unusually active option classes on open February 8th
- Ionis Pharmaceuticals: FDA grants Fast Track designation to eplontersen
- Options Volatility and Implied Earnings Moves Today, February 08, 2024
- Deutsche cut AstraZeneca to Sell on ‘thoroughly underwhelming’ Q4